Foster City, CA, September 19, 2007 – Entelos, Inc. (LSE: ENTL), a leading life sciences company that leverages its predictive efficacy and safety platforms and “virtual patients” to develop drugs and support pharmaceutical R&D, is pleased to announce that a fund managed by Abingworth Management Limited, one of the Company’s early venture investors through a related fund and currently a major shareholder through several of its investment funds, has entered into an agreement to subscribe for 3,783,314 Entelos shares at 26.55 pence per common share.

Transaction details
Abingworth Bioventures IIa LP has invested $2 million to acquire 3,783,314 new Entelos shares. The subscription price is based on the 10 days trading average closing price of 26.55p prior to 18 Sep 2007, the last practicable date prior to this announcement, and represents a premium of approximately 6.2% to the share price of 25p on 18 Sep 2007. All of the shares to be issued will be subject to a lock up agreement which provides that, subject to certain limited exemptions (including with the prior written consent of Evolution Securities Limited), the new shares will not be disposed of for 12 months following the closing date. An application will be made for the new Entelos shares to be admitted to trading on AIM and the Company expects admission to become effective on 25 September 2007. Following the subscription, funds managed by Abingworth Management Limited will hold 9,277,163 Entelos shares representing 13.9% of the enlarged share capital of Entelos.

“We believe that Entelos’ recent acquisition of Iconix Biosciences combines best-in-class predictive sciences for drug efficacy and safety testing,” commented Jonathan MacQuitty, Ph.D., a former director of the Company and a Partner at Abingworth. “Our most important investment criteria are strong management and a novel technology that offers significant improvements over current approaches. We are not generally looking for incremental improvements over existing technologies; but rather, we seek companies with breakthroughs that will usher in a paradigm shift to advance discovery of new medicines in major therapeutic areas.”

James Karis, President and CEO of Entelos added: “We are pleased that Abingworth, a major investor in both Entelos and Iconix, has agreed to increase its holdings in our expanded company. We believe this signals confidence in our strategy to leverage our efficacy, safety, and biology discoveries into drug ownership opportunities. The Company will utilise the proceeds of the subscription to facilitate the Company’s growth strategy. ”

For further information please contact:
Entelos, Inc.
James Karis, President and CEO
Alan Blazei, CFO
Thereafter on Tel +1 650 572 5400

Abingworth Management, Inc
Jonathan MacQuitty, PhD
President and Director
Tel: +1 650 926 0600

Evolution Securities
Tim Worlledge, Director
Tel +44 (0) 20 7071 4300
Bobbie Hilliam, Associate Director

Buchanan Communications
Lisa Baderoon
Mary-Jane Johnson
Tel +44 (0) 20 7466 5000

Notes for Editors

About Entelos
Entelos, Inc. (www.entelos.com) is a US-based life sciences company applying next-generation predictive technologies to revolutionize the way medicines are discovered, developed, and utilized. The Company leverages its proprietary in silico disease models, “virtual patients”, and toxicology reference systems to develop safer and more effective drugs and support pharmaceutical R&D and commercialization. In addition to internal drug programs in rheumatoid arthritis and women's health, Entelos provides customized technology and research services to global pharmaceutical and health-care companies in cardiovascular diseases, asthma, obesity, diabetes, hematopoeisis (anemia), cholesterol metabolism, and skin sensitization. The company is also developing a model in oncology and is collaborating with the FDA to build a model of drug-induced liver toxicity. Entelos also offers cost-effective drug development capabilities through its strategic alliance with India-based Jubilant Biosys.

About Abingworth
Abingworth is a long-established venture capital firm dedicated to the life sciences sector on both sides of the Atlantic. The company invests across all stages of development, including early-stage as well as public companies. Abingworth has funds under management of over $1.25 billion. Abingworth has provided backing for more than 100 unquoted life science businesses. More than 70% of these have gone public or have been merged into, or acquired, by larger companies. Founded in 1973, Abingworth has offices in London, Cambridge (UK), Menlo Park (California) and Boston. Successful investments have included Alnylam Pharmaceuticals, Aurora Biosciences, Aviron, GelTex Pharmaceuticals, Gilead Sciences, Healtheon, IDEC Pharmaceuticals, Pharmion, PowderMed and Solexa. For a full list of Abingworth’s portfolio companies please visit the website at www.abingworth.com.

Entelos is a registered trademark of Entelos, Inc. PhysioLab is a trademark and service mark of Entelos, Inc.
All other trademarks are the property of their registered owners.

  www.entelos.com